What is Evista, and what is it used for?
Evista is the brand name for raloxifene, a prescription medicine. It is used to help prevent and treat osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in certain high-risk people. It works by acting on estrogen receptors in the body. [1]
How does Evista work?
Raloxifene is a selective estrogen receptor modulator (SERM). That means it can act like estrogen in some tissues (such as bone) and block estrogen’s effects in others (such as breast tissue). This helps protect bone while lowering estrogen-related stimulation of breast cancer risk. [1]
How is Evista typically taken?
Evista is taken by mouth as a daily tablet. The exact dose and suitability depend on the reason it is prescribed and the patient’s overall risk factors. Follow the prescribing clinician’s instructions. [1]
Who should not take Evista (key safety concerns)?
Evista carries important safety warnings, especially around blood clots and stroke risk. It is generally not used in people with a history of certain thromboembolic (clot) conditions, and it requires careful assessment in people with cardiovascular risk factors. [1]
What side effects do people report with Evista?
Commonly reported side effects can include hot flashes and leg cramps. More serious risks relate to venous blood clots and stroke, which is why clinicians assess risk before prescribing and monitor for symptoms. [1]
What happens if you stop taking Evista?
Because Evista is used to reduce long-term risks (like bone loss), stopping can reduce its protective effect. The right timing to stop or switch treatment depends on the original indication and a clinician’s plan. [1]
What alternatives exist if Evista isn’t a fit?
Alternatives depend on whether the goal is osteoporosis treatment/prevention or breast cancer risk reduction. Options typically include other osteoporosis therapies and different endocrine risk-reduction strategies, selected based on age, fracture risk, and clot/stroke risk. [1]
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020-140